Search clinical trials for: JAK2 kinase inhibitor

Total 68255 results

Peking University Cancer Hospital & Institute

Recruiting

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Digestive System Cancers

China
University Health Network, Toronto

Recruiting

Pilot Study on Trametinib for Surgical Unruptured AVMs (OZUHN-017)

Arteriovenous Malformations

Canada
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis

Crohn Disease

China
Mayo Clinic
Bristol-Myers Squibb

Recruiting

A Study of Deucravacitinib to Treat LPP and FFA

Lichen Planopilaris

United States
AbbVie

Not yet recruiting

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Non-Small Cell Lung Cancer
Novartis Pharmaceuticals

Recruiting

Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France (ASSURE-3)

Chronic Myeloid Leukemia

France
Takeda

Not yet recruiting

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Ulcerative Colitis

United States
National Cancer Institute (NCI)

Recruiting

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Inherited Bone Marrow Failure Syndrome | Familial Platelet Disorder With Predisposition to Myeloid Malignancies

United States
Tongji Hospital

Not yet recruiting

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Hepatocellular Carcinoma

China
Jeeyun Lee

Not yet recruiting

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

Stomach Neoplasm
Shenzhen TargetRx, Inc.
Sun Yat-sen University

Recruiting

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

China
Jin Li

Not yet recruiting

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

Relapsed Ovarian Cancer
University of Milano Bicocca

Recruiting

Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer (MUT-ONC)

Lung Cancer

Italy
Sanofi

Recruiting

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction (ROCKaspire)

Lung Transplant Rejection

Belgium, Finland, Israel, Italy, Hungary, Spain, Netherlands, United States, France, Czechia
Hunan Province Tumor Hospital
Xiangya Hospital of Central South University

Recruiting

The Efficacy and Safety of IBI363 in Solid Tumors (Promise)

Advanced Solid Tumor

China
Leiden University Medical Center
Novartis

Recruiting

NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) (NEO-ATACT)

Anaplastic Thyroid Cancer

Netherlands
Assiut University

Not yet recruiting

Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients

Metastatic Breast Cancer

Saudi Arabia
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)

China, Taiwan, United States, Australia, Israel, Hong Kong, Chile, Korea, Republic of, Canada, Malaysia, Thailand
BeiGene

Recruiting

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

CLL

United States, Australia, Spain, New Zealand, Korea, Republic of, Canada, Poland, Brazil, Puerto Rico, China
The Second Affiliated Hospital of Kunming Medical...

Not yet recruiting

Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients

Acute Myeloid Leukemia | Decitabine | Venetoclax | Elderly AML Patients | Unfit, New-diagnosis AML

China
China Medical University Hospital

Not yet recruiting

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer | EGFR Gene Mutation | EGFR-TKI Resistant Mutation
Sun Yat-sen University

Recruiting

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Sintilimab | Lenvatinib

China
Jonathan Riess
National Cancer Institute (NCI)

Not yet recruiting

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland

Not yet recruiting

Zanubrutinib in Primary Cold Agglutinin Disease (HOVON169CAD)

Lymphoma

Norway, Netherlands, Denmark, Belgium
Genoss Co., Ltd.

Recruiting

Efficacy of OSFIT Drug-Eluting Stent in Coronary Ostial Artery Stenosis

Coronary Artery Disease | Drug-eluting Stent

Korea, Republic of
Hoffmann-La Roche

Recruiting

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Belgium, Korea, Republic of, United States, Canada, China, Italy, France, Brazil, Australia, Argentina, Hong Kong, Portugal, Spain, Taiwan, India, Costa Rica, Israel, Thailand, Germany, New Zealand, Poland, Chile, Colombia, Guatemala, H...
Lebanese University
Haykel Hospital

Recruiting

Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms (CAT_PB)

Cardiovascular Diseases | Immune System Diseases | Cancer | Breast Cancer | Hepatocellular Carcinoma | Lung Cancer | Chemotherapy | Solid Tumor | Prostate Cancer | Thromboembolism | Colon Cancer | Immunotherapy | Inflammatory Diseases

Lebanon
Tang-Du Hospital

Not yet recruiting

Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions

Traumatic Brain Injury

China
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...

Not yet recruiting

Pharmacogenomics IND EXEMPT SNP Clinical Study - Crizotinib and Single Nucleotide Polymorphisms (Drugs-SNPs)

Non-Small Cell Lung Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Not yet recruiting

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Estrogen-receptor-positive Breast Cancer | HER2/Neu-Negative Breast Cancer | Advanced Breast Cancerv

United States
National University Hospital, Singapore

Recruiting

Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

NSCLC

Singapore
Sun Yat-sen University

Recruiting

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Camrelizumab | Lenvatinib

China
Beijing 302 Hospital

Recruiting

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

Liver Neoplasms

China
Goethe University
German Federal Ministry of Education and Research; Deutsche Leukämie- & Lymphom-Hilfe

Recruiting

Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT (GMALL-EVOLVE)

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Germany
Institut Paoli-Calmettes

Not yet recruiting

Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE (VEN-R DASA)

Acute Myeloid Leukemia
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
AVEO Pharmaceuticals, Inc.

Recruiting

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Sun Yat-sen University

Not yet recruiting

Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

NSCLC | BRAF V600 Mutation | MET Exon 14 Mutation

China
Ascentage Pharma Group Inc.
HealthQuest Pharma Inc.

Recruiting

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.

Ph+ ALL

China
Region Örebro County
Helsinki University Central Hospital; Hospital Clinic of Barcelona; University... and other collaborators

Recruiting

Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients (IMPORTANT)

Quality of Life | Advanced Breast Cancer | Metastatic Breast Cancer | Toxicity | Older Patients

Sweden, Finland, Greece, Italy, Norway, Spain
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

Palmoplantar Psoriasis | Genital Psoriasis

United States, Germany, Spain, Italy, Poland, Argentina, Canada
Jennifer Eva Selfridge

Not yet recruiting

Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

Siewert Type II Adenocarcinoma of Esophagogastric Junction | Adenocarcinoma Esophagus | Siewert Type I Adenocarcinoma of Esophagogastric Junction | Locally Advanced Adenocarcinoma
Bangabandhu Sheikh Mujib Medical University, Dhaka...
Aristopharma Ltd

Recruiting

Effectiveness of Tofacitinib in Systemic Sclerosis

Efficacy of Tofacitinib in the Systemic Sclerosis

Bangladesh
Northside Hospital, Inc.
Sanofi

Recruiting

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

Chronic Graft Versus Host Disease

United States
Peking Union Medical College Hospital

Not yet recruiting

Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation

Liver Transplant; Complications | Recurrent Osteosarcoma | Hepatocarcinoma | High-Risk Cancer

China
Novartis Pharmaceuticals

Recruiting

A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients.

Chronic Spontaneous Urticaria

Switzerland, Australia, Italy, Spain, France, Germany, Korea, Republic of, Netherlands, Taiwan, India, Czechia, Hungary, Thailand, Turkey, Malaysia, Canada, Argentina, Bulgaria, Slovakia, Brazil, Poland
Sun Yat-sen University
First People's Hospital of Foshan; The First Affiliated Hospital, Guangzhou... and other collaborators

Recruiting

Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC (HAIC)

Hepatocellular Carcinoma | Chemotherapy Effect | Chemotherapeutic Toxicity

China
Merck Sharp & Dohme LLC

Recruiting

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Solid Tumor | Endometrial Cancer | Cutaneous Squamous Cell Carcinoma

Canada, Australia, Taiwan, Malaysia, United States, Netherlands, Turkey, France
RenJi Hospital
Shanghai Zhongshan Hospital; Ruijin Hospital

Recruiting

A Study of Cadonilimab（AK104） Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy

China
LianBio LLC

Recruiting

BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations

NSCLC

China

Search clinical trials for: JAK2 kinase inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations